Citations

Clear

585 citation(s) found for "Tran, Ha".

STEM-20. REGULATION OF GLIOMA STEM CELL MAINTENANCE AND THERAPEUTIC RESISTANCE BY EGFR MISSENSE MUTATIONS
Weaver, Sidney , Miller, Aunay , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Kloss, Jean , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v37-v37

10.1093/neuonc/noad179.0145 Get It

Abstract Glioblastoma (GBM) tumors contain a subpopulation of glioma stem cells (GSC) which can escape therapeutic effects through self-renewal and invasion. Epidermal growth factor receptor (EGFR) mutations are the most common alteration in GBM. EGFRvIII (deletion of exons 2-7) is observed in GBM (20-25%) resulting in a constitutively activated EGFR receptor. In addition, extracellular domain missense point mutations, (e.g. G598V, A289V, R108K) are observed in GBM (14.4%). These missense mutations in the EGFR extracellular domain also induces a highly active receptor by enhancing ligand binding. Earlier reports have shown that these EGFR missense point mutations have exhibited therapeutic resistance; however, the molecular mechanism of these missense point mutations in GBM remains unknown. Previous studies in our lab showed that EGFRvIII promotes GSC maintenance and therapeutic resistance via oligodendrocyte transcription factor 2 (OLIG2) signaling. OLIG2 is universally expressed in glioma and essential for reprogramming GBM cells into stem-like tumor cells. Increased OLIG2 expression promotes invasion, growth, proliferation, and survival. Here we report an increase in OLIG2 protein expression in GSCs harboring EGFR-G598V or EGFR-A289V mutations, suggesting these mutations may support stemness properties in GBM tumors. GSC expressing these point mutations display increased self-renewal, growth, and survival. In addition, EGFR-G598V and EGFR-A289V trigger distinct downstream signaling pathways in GSCs to regulate OLIG2 function. Hence, we hypothesize that GBM tumors harboring EGFR missense mutations (G598V, A289V) influence stem cell properties via multiple pathways to evade therapeutic effects and inhibiting these different signaling pathways will decrease therapeutic resistance in GBM. Understanding the mechanism of these EGFR mutations may lead to improved therapeutic strategies for GBM patients.
ANGI-05. CDKN2A/B HOMOZYGOUS DELETION IN IDH-MUTANT ASTROCYTOMA ALTERS TUMOR CELL INVASION AND VASCULAR FORMATION
Grief, Dustin, Sereduk, Christopher, Hu, Leland , Loftus, Joseph C. , D’Angelo, Fulvio , Caruso, Francesca Pia , Sereduk, Chris , Ceccarelli, Michele , Tran, Nhan L. , Ensign, Shannon P. Fortin

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v2-v2

10.1093/neuonc/noad179.0005 Get It

Abstract High-grade gliomas represent the most common type of primary adult malignant brain tumor historically diagnosed and graded from histologic criteria alone. Gliomas harboring isocitrate dehydrogenase (IDH) 1 or 2 mutations are associated with lower grade tumors and portend a favorable prognosis relative to IDH-wildtype glioma. However, molecular profiling has identified additional alterations in lower grade gliomas that confer an aggressive high-grade phenotype and a worse clinical prognosis. Of these, the loss of CDKN2A/B in IDH-mutant astrocytoma is the strongest implicated alteration and is sufficient to define a grade 4 tumor regardless of histologic grade. However, there remain no effective therapies targeted at molecular subgroups in aggressive gliomas to date. Here, we sought to elucidate the biologic pathways and functional outcomes associated with the acquisition of high-grade behavior under loss of CDKN2A/B in IDH-mutant astrocytoma to inform future therapeutic strategies. We analyzed a cohort of patient IDH-mutant astrocytomas with whole exome and RNA sequencing data and found several candidate genes/pathways regulated concurrent with CDKN2A/B loss, including regulators of embryonic development, extracellular matrix organization and regulation of vascular processes. Moreover, we identified 1 tumor that displayed intratumoral heterogeneity of CDKN2A/B expression across biopsies. Using grade 4 IDH-mutant astrocytoma patient-derived (PDX) and established cell-lines harboring CDKN2A/B homozygous deletion, we then stably re-expressed cell cycle regulators p14, p15, and p16 using a Tet-inducible lentiviral system and confirmed their decreased proliferation as compared to parental lines. IDH-mutant cell lines with re-expression of p14, p15 or p16 were characterized by differential transcription factor activation and distinct vascular formation patterns as compared to parental lines. These lines also displayed an increased cell migration and invasive potential and were associated with enhanced integrin signaling through integrin beta-3. Together, our work supports a hypothesis of regional tumor evolution with distinct biologic phenotypes across IDH-mutant gliomas.
Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics
Signorelli, Jessie , Tran, Thuy , Sirek, Marie E. , Díaz-Rohena, Yarelis, Taraba, Jodi L. , Muluneh, Benyam , Basu, Nayanika, Lilly, Jennifer, Darling, Julianne O. , Díaz-Rohena, Yarelis, Taraba, Jodi L , Lilly, Jennifer

Mayo Clinic

Journal of Oncology Pharmacy Practice | October 30, 2023 | Volume: 30 | Issue: 8 | Pages: 1307-1316

10.1177/10781552231208442 | PMID 37899586 Get It

Introduction To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics. Methods A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence. A second literature search was conducted to identify questions targeting specific barriers from validated adherence questionnaires. Once a finalized draft was complete, the risk assessment tool was built into an electronic survey where a risk category can be automatically calculated for the patient. Results The six most impactful factors affecting compliance to oral oncolytics were identified as patient's confidence, health literacy, perception of treatment, quality of life, social support, and complexity of chemotherapy regimen. A six-item questionnaire was created with five patient-directed questions and one clinician-directed question. Examples and descriptions were provided for clinicians to consider when categorizing complexity of a regimen. The tool was designed for responses to each question to be indexed into categories through a 10-point system. Results will be stratified into low, moderate, or high risk for nonadherence. Conclusion The creation of a tool to predict nonadherence prior to starting therapy is an unmet need for patients initiating oral oncolytics. The aim of this tool is to meet those needs and better guide clinicians to provide patients with strategies to better manage nonadherence. Next steps include tool validation and piloting in clinical practice.
Senescent and disease-associated microglia are modifiable features of aged brain white matter
Schafer, Marissa , Carver, Chase, Gomez, Paul , Rodríguez, Sónia , Kachergus, Jennifer M., Liu, Yi , Shi, Ji , Tran, Tommy, Thompson, E. Aubrey , Carver, Chase M., Gomez, Paul T, Rodriguez, Sonia L, Thompson, E Aubrey , Schafer, Marissa J , Rodriguez, Sonia, Wang, Liguo , Melov, Simon

Mayo Clinic

No container title available | October 30, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3467812/v1 | PMID 37961365 Get It

Abstract Brain white matter tracts undergo structural and functional changes linked to late-life cognitive decline, but the cellular and molecular contributions to their selective vulnerability are not well defined. In naturally aged mice, we demonstrate that senescent and disease-associated microglia (DAM) phenotypes converge in hippocampus-adjacent white matter. Through gold-standard gene expression and immunolabeling combined with high-dimensional spatial mapping, we identified microglial cell fates in aged white matter characterized by aberrant morphology, microenvironment reorganization, and expression of senescence and DAM markers, including galectin 3 (GAL3/Lgals3), B-cell lymphoma 2 (Bcl2), and cyclin dependent kinase inhibitors, including Cdkn2a/p16ink4a. Pharmacogenetic or pharmacological targeting of p16ink4a or BCL2 reduced white matter GAL3+ DAM abundance and rejuvenated microglial fimbria organization. Our results demonstrate dynamic changes in microglial identity in aged white matter that can be reverted by senotherapeutic intervention to promote homeostatic maintenance in the aged brain.
A 7-Year-Old Boy with Fever and Dark Urine
Chuang, Tony M. , Bu, Lihong , Opp, Derek N., Potretzke, Theodora A. , Dorn, Charlotte S. Van , Tran, Cheryl L. , Van Dorn, Charlotte S, Huskins, W. Charles , Dearani, Joseph A. , Hanna, Christian

Mayo Clinic

NEJM Evidence | October 24, 2023 | Volume: 2 | Issue: 11 | Pages: No page available

10.1056/evidmr2300191 | PMID 38320528 Get It

Weakly-Supervised Transfer Learning With Application in Precision Medicine
Mao, Lingchao , Wang, Lujia , Hu, Leland , Eschbacher, Jenny, León, Gustavo De , Singleton, Kyle , Urcuyo, Javier , Sereduk, Chris , Tran, Nhan L. , Swanson, Kristin R. , Li, Jing , Singleton, Kyle W , Curtin, Lee A, Hawkins-Daarud, Andrea, Mao, Lingchao , Swanson, Kristin R , Tran, Nhan L , Leon, Gustavo De, Curtin, Lee , Hawkins‐Daarud, Andrea

Mayo Clinic

IEEE Transactions on Automation Science and Engineering | October 23, 2023 | Volume: 21 | Issue: 4 | Pages: 6250-6264

10.1109/tase.2023.3323773 | PMID 40757183 Get It

Lymphatic Mapping with Contrast-enhanced Ultrasound for Lymphaticovenous Anastomosis Surgery: How We Do It
Jang, Samuel , Bustos, Samyd S. , Chen, Austin D. , Zheng, Eugene E., Hesley, Gina K. , Brinkman, Nathan , Carter, Jill S., Tran, Nho V. , Fahradyan, Vahe , Lee, Christine U. , Bustos, S S , Fahradyan, Vahe , Zheng, Eugene E.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | October 12, 2023 | Volume: 11 | Issue: 10 | Pages: e5328

10.1097/gox.0000000000005328 | PMID 37842077 Get It

Summary: Lymphaticovenous anastomosis (LVA) surgery is an effective surgery for the treatment of lymphedema in the extremities. Indocyanine green lymphography is the reference standard for visualizing lymphatics for LVA surgery, but it has several limitations; most notably, superficial dermal congestion can mask deeper lymphatic vessels. To overcome the limitations, we add contrast-enhanced ultrasound (CEUS) lymphography. We have previously reported that CEUS lymphography can identify lymphatic vessels for LVA surgery that indocyanine green lymphography does not. Here, we describe how we perform CEUS lymphography, including workflow, technique, and documentation. Before informed consent, the patient must be screened for possible adverse reactions to microbubbles. The procedure involves multiple intradermal injections of the microbubble agent at various sites along the extremity. After each injection, imaging for microbubble uptake by lymphatic vessels is performed using an ultrasound scanner with contrast-specific software. We use sulfur hexafluoride lipid-type A microspheres (Lumason/SonoVue; Bracco Suisse SA), but we are investigating the performance of other Food & Drug Administration–approved microbubble agents for CEUS lymphography. Having a systematic approach to marking the skin can mitigate the hindrance of marking over ultrasound coupling gel. Another benefit of CEUS lymphography is the rapid identification of neighboring veins compatible in size and location for anastomosis. We hold regular scheduled multidisciplinary meetings for coordination of care, discussion of outcomes, quality assurance, and ongoing innovation.
Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study
Palmer, Mathias Earl, Jin, Zhaohui , Palmer, Mathias E, Gile, Jennifer J, Jin, Zhaohui , Zemla, Tyler J, Gile, Jennifer , Storandt, Michael H. , Zemla, Tyler , Tran, Nguyen H. , Mahipal, Amit

Mayo Clinic

Cancers | October 6, 2023 | Volume: 15 | Issue: 19 | Pages: 4867

10.3390/cancers15194867 | PMID 37835561 Get It

Background: Lenvatinib, a multikinase inhibitor, is an FDA-approved treatment for advanced hepatocellular carcinoma (HCC) in the first-line setting. Recent trial data have established atezolizumab plus bevacizumab as well as tremelimumab plus durvalumab as preferred first-line treatment options for advanced HCC. The role of lenvatinib following progression on immunotherapy in patients with advanced HCC remains unclear. Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010 and 2021 at the Mayo Clinic in Minnesota, Arizona, and Florida who received immunotherapy followed by lenvatinib. Median overall survival and progression-free survival analyses were performed using the Kaplan–Meier method, and responses were determined using RECIST 1.1. Adverse events were determined using CTCAE v 4.0. Results: We identified 53 patients with advanced HCC who received lenvatinib following progression on immunotherapy. Forty five (85%) patients had a Child Pugh class A at diagnosis, while 30 (58%) patients were still Child Pugh A at time of lenvatinib initiation. Lenvatinib was administered as a second-line treatment in 85% of the patients. The median PFS was 3.7 months (95% CI: 3.2–6.6), and the median OS from the time of lenvatinib initiation was 12.8 months (95% CI: 6.7–19.5). In patients with Child Pugh class A, the median OS and PFS was 14 and 5.2 months, respectively. Race, gender, and Child Pugh class was associated with OS on multivariate analysis. Discussion: Our study, using real-world data, suggests that patients benefit from treatment with lenvatinib following progression on immunotherapy in advanced HCC. The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown, and these results need to be validated in a clinical trial.
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions
Wang, Minggui , Ge, Lizhao , Chen, Liang , Komarow, Lauren , Hanson, Blake , Cober, Eric , Alenazi, Thamer H. , Xie, Qing , Liu, Zhengyin , Li, Lanjuan , Yu, Yunsong , Gao, Hainv , Figueroa, Jairo, Herc, Erica , Córdova, Ezequiel , Weston, Gregory , Kaye, Keith S. , Dhar, Sorabh , Munita, José M. , Salata, Robert A. , Vilchez, Samuel, Stryjewski, Martín E. , Iovleva, Alina , Evans, Scott , Baum, Keri, Hill, Carol , Kreiswirth, Barry N. , Patel, Robin , Arias, Cesar A, Chambers, Henry F. , Fowler, Vance G. , Satlin, Michael J. , Investigators, Multi-Drug Resistant Organism Network, Zhang, Fujie , Castelnuovo, Valentina Di, Gutierrez, Jose Millan Oñate, Evans, Beth , Cross, H. R. , Arias, Rebekka M. , Fowler, Vance G, Ordóñez, Karen , Li, Linghua , Kreiswirth, Barry N , Desai, Samit, Rioseco, María Luisa, Vilchez, Samuel, Sánchez, Marisa , Valderrama, Sandra , Figueroa, Jairo, Arias, Cesar A, Dinh, An Q , Panesso, Diane, Rydell, Kirsten, Tran, Truc T. , Jiang, Jianping , Xu, Xiaogang , Spencer, María, Marshall, Steven H. , Rudin, Susan D., Greenwood-Quaintance, Kerry, Schmidt-Malan, Suzannah M., Revolinski, Sara , Wortmann, Glenn , Kalayjian, Robert C. , Ostrowsky, Belinda , Patel, Gopi , Eiras, Daniel , Garcia-Diaz, Julia, Farrell, John J. , Paterson, David L, Kaye, Keith S, Waters, Mary Jo, Eilertson, Brandon , Ng, Oon Tek , De, Partha Pratim, Chew, Kean Lee , Smitasin, Nares , Gallagher, Jason C , Leroi, Marcel , McCarty, Todd P , Lautenbach, Ebbing , Hanson, Blake, Perez, Federico, Banerjee, Ritu , Dhar, Sorabh, Westblade, Lars F. , Yu, Yunsong , Cordova, Ezequiel , Kaye, Keith S , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Chen, Liang , Wang, Minggui , Munita, Jose M , Reyes, Jinnethe , Zong, Zhiyong , Kanj, Souha S. , Tambyah, Paul Anantharajah , Garcia‐Diaz, Julia , Villegas, María Virginia , Kreiswirth, Barry N , Paterson, David L. , Arias, Cesar A, Bonomo, Robert A. , Fowler, Vance G. , Doi, Yohei , Investigators, Multi-Drug Resistant Organism Network, Lok, Judith J. , Richter, Susan, Anderson, Deverick J. , Evans, Beth, Cross, Heather R, Fowler, Vance G, Jacob, Jesse T. , Manca, Claudia , Vilchez, Samuel, Figueroa, Jairo, Arias, Cesar A, Hu, Fupin , Su, Jiachun , Wang, Minggui, Xu, Xiaogang, Yang, Yang, Huskins, W. Charles , Greenwood‐Quaintance, Kerryl E. , Kim, Angela , Garcia-Diaz, Julia, Salcedo, Soraya , Henderson, Andrew , Paterson, David L, Kaye, Keith S, Fries, Bettina C. , Marimuthu, Kalisvar , Peleg, Anton Yariv , Xiao, Yonghong , Garner, Omai B. , Abbo, Lilian M. , Han, Jennifer , Wong, Darren , Hanson, Blake, Díaz, Lorena

Mayo Clinic

Clinical Infectious Diseases | September 22, 2023 | Volume: 78 | Issue: 2 | Pages: 248-258

10.1093/cid/ciad556 | PMID 37738153 Get It

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb. Methods In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis. Results Of 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases. Conclusions CRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.
BULK RNA-SEQ DECONVOLUTION OF IMAGE-LOCALIZED HIGGRADE GLIOMA BIOPSIES REVEALS MEANINGFUL CELLULAR STATES
Bond, Kamila M. , Vélez, Sebastián, Urcuyo, Javier , León, Gustavo De , Langworthy, Jazlynn , Sereduk, Christopher, Singleton, Kyle , Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi P. , Smith, Kris A. , Donev, Kliment , Mrugała, Maciej M. , Hu, Leland , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Curtin, Lee , Velez, Sebastian, Hawkins‐Daarud, Andrea , Leon, Gustavo De, Sereduk, Chris , Jackson, Pamela , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie C. , Al‐Dalahmah, Osama , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | September 16, 2023 | Volume: 25 | Issue: Supplement_3 | Pages: iii2-iii2

10.1093/neuonc/noad147.005 Get It

Abstract AIMS High-grade glioma continues to have dismal survival with current standard-of-care treatment, owing in part to its intra- and inter-patient heterogeneity. Typical diagnostic biopsies are taken from the dense tumor core to determine the presence of abnormal cells and the status of a few key genes (e.g. IDH1, MGMT). However, the tumor core is typically resected, leaving behind possibly genetically, transcriptomically and/or phenotypically distinct invasive margins that repopulate the disease. As these remaining populations are the ones ultimately being treated, it is important to know their compositional differences from the tumor core. We aim to identify the phenotypic niches defined by the relative composition of key cellular populations and understand their variation amongst patients. METHOD We have established an image-localized research biopsy study, that samples from both the invasive margin and tumor core. From this protocol, we currently have 202 samples from 58 patients with available bulk RNA-Seq, collected between Mayo Clinic and Barrow Neurological Institute. Using a single-cell reference dataset from our collaborators at Columbia University, we used CIBERSORTx, a deconvolution method, to predict relative abundances of 7 normal, 6 glioma, and 5 immune cell states for each sample. RESULTS We find that these cell state abundances connect to patient survival and show regional differences. For example, proneural glioma states were higher in invasive regions, whereas proliferative and mesenchymal states were higher in the tumor core. CONCLUSIONS Our analysis demonstrates a need to characterize the residual tissue following glioma resection to better understand the recurrent disease.